Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

BACKGROUND: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end stage kidney disease. Antifibrotic agents, such as tumor necrosis factor α (TNF-α) antagonists, are a promising strategy to slow or halt the decl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Joy, Melanie S., Gipson, Debbie S., Powell, Leslie, MacHardy, Jacqueline, Jennette, J. Charles, Vento, Suzanne, Pan, Cynthia, Savin, Virginia, Eddy, Allison, Fogo, Agnes B., Kopp, Jeffrey B., Cattran, Daniel, Trachtman, Howard
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804955/
https://ncbi.nlm.nih.gov/pubmed/19932542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2009.08.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados